Diabetic Nephropathy – Pipeline Review, 2019

A clinical abnormality characterized by persistent albuminuria, reduction in glomerular filtration rate (GFR) and elevated arterial blood pressure leading to the deterioration of proper functioning of kidney in patients with type 1 and type 2 diabetes is termed as diabetic nephropathy. It is the common cause of chronic kidney disease worldwide. There are five stages of diabetic nephropathy. Initially, the person may not experience any symptoms, but at stage 4 or 5 they may experience symptoms like swollen ankles and feet due to water retention, dark urine due to blood in urine, worsening blood pressure control, protein in the urine, nausea, vomiting, and loss of appetite.

The main aim of the prevention and treatment of diabetic nephropathy is to maintain and control blood glucose levels and blood pressure levels. Current treatment of diabetic nephropathy includes medications and dietary changes at the initial stages. Drugs like Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) can help lower blood sugar levels and protect kidney functions. Later-stage treatment includes dialysis and kidney transplant.

According to the Centers for Disease Control and Prevention (CDC) in 2019, 15% of the U.S population is estimated to suffer from chronic kidney diseases (CKD). This increasing prevalence of kidney diseases is elevating the focus of pharmaceutical companies towards developing new treatment options against diabetic nephropathy. For instance; LMB763, which is being studied by Novartis AG, is currently in phase-2 clinical trials for the study of safety, tolerability, and efficacy of LMB763 in patients with diabetic nephropathy.

At present, around 48% of the pipeline candidates for diabetic nephropathy are in the phase-2 clinical stage. Maximum studies for diabetic nephropathy are sponsored by pharmaceutical industries.

Report Description

The report on ‘Diabetic Nephropathy – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for diabetic nephropathy. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Diabetic Nephropathy.

The report on ‘Diabetic Nephropathy– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Diabetic Nephropathy
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Diabetic Nephropathy
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary